Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NCIC Clinical Trials Group
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2015-01098 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2020-08-15 |
2025-02-12 |
Primary Endpoints|Start Date|Study Completion Date |
|
| I177 | P1 |
Completed |
Lymphoma |
2012-03-13 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2024 |
PubMed |
An allosteric mechanism for potent inhibition of SARS-CoV-2 main proteinase. |
|
01/19/2024 |
PubMed |
Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors. |
|
11/14/2023 |
PubMed |
A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration. |